PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 22.2

Change

-0.25 (-1.11)%

Market Cap

N/A

Volume

0.52M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-1.12 (-1.62%)

USD 10.78B
DOCS Doximity Inc

+0.66 (+1.58%)

USD 7.70B
WEAV Weave Communications Inc

-0.11 (-0.91%)

USD 0.86B
AMWL American Well Corp

-0.34 (-3.47%)

USD 0.15B
MPLN MultiPlan Corporation

+0.65 (+9.00%)

USD 0.12B
OWLT Owlet Inc

+0.23 (+5.30%)

USD 0.07B
TDOC Teladoc Inc

-0.06 (-0.71%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

+1.24 (+4.48%)

N/A
VEEV Veeva Systems Inc Class A

+4.30 (+2.10%)

N/A

ETFs Containing PHR

W311:XETRA HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

-0.07 (-0.68%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

-0.06 (-0.68%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

-0.05 (-0.68%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

-0.04 (-0.68%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.10% 70% C- 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.10% 70% C- 16% F
Trailing 12 Months  
Capital Gain 19.16% 80% B- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.16% 80% B- 47% F
Trailing 5 Years  
Capital Gain -11.16% 50% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.16% 50% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain 13.21% 80% B- 75% C
Dividend Return 13.21% 80% B- 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.15% 60% D- 12% F
Risk Adjusted Return 19.38% 70% C- 38% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector